Cyclerion Therapeutics (NASDAQ:CYCN) Trading Down 1.6% – Time to Sell?

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) fell 1.6% on Wednesday . The stock traded as low as $3.60 and last traded at $3.63. Approximately 11,369 shares traded hands during trading, a decline of 47% from the average session volume of 21,285 shares. The stock had previously closed at $3.69.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Cyclerion Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Cyclerion Therapeutics currently has an average rating of “Sell”.

Cyclerion Therapeutics Stock Performance

The company has a market cap of $15.72 million, a P/E ratio of -2.67 and a beta of 1.74. The business’s fifty day moving average is $3.30 and its two-hundred day moving average is $2.50.

Cyclerion Therapeutics (NASDAQ:CYCN) last issued its earnings results on Tuesday, May 12th. The company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($17.20) by $16.44. Cyclerion Therapeutics had a negative return on equity of 62.10% and a negative net margin of 170.11%. Analysts expect that Cyclerion Therapeutics, Inc. will post -1.2 EPS for the current fiscal year.

Institutional Investors Weigh In On Cyclerion Therapeutics

An institutional investor recently bought a new position in Cyclerion Therapeutics stock. Two Sigma Investments LP acquired a new stake in shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned about 0.40% of Cyclerion Therapeutics at the end of the most recent quarter. 75.62% of the stock is owned by hedge funds and other institutional investors.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.